HempNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Shareholders Approve Proposed Forward Stock Split

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced that during its annual general and special meeting of shareholders on May 14, 2018, the proposed forward stock split of PreveCeutical’s issued and outstanding common shares on the basis of five new common shares for each one existing common share was approved by the company’s shareholders. Subject to approval by the Canadian Securities Exchange, the record date for the stock split will be May 24, 2018. On or about May 30, 2018, the company’s transfer agent will issue the additional number of common shares to shareholders of record as a result of the stock split. “We believe the stock split demonstrates the company’s continued commitment to broaden its shareholder base and we anticipate that the stock split will make PreveCeutical’s securities more accessible to investors and enhance liquidity for shareholders,” PreveCeutical CEO, president and chairman Stephen Van Deventer stated in the news release.

To view the full press release, visit http://cnw.fm/wm4Jr

About PreveCeutical Medical Inc.

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the company’s website. For more information about PreveCeutical, please visit www.PreveCeutical.com

More from CannabisNewsBreaks

• HempNewsBreaks – Golden Triangle Ventures Inc. (OTC: GTVH) Restructures $7 Million in Legacy Debt, Secures Repurchase Option
• HempNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Positive Preclinical Results for INM-901 in Alzheimer’s Neuroinflammation Model
• HempNewsBreaks – CannabisNewsWire Named Official Newswire of 2025 Cannabis Means Business Expo in NYC 

About HempWire

HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.

For more information please visit https://www.hempwire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/

HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net